- Aniridia treatment refers to the therapeutic management of congenital or acquired absence of the iris, a rare genetic condition often linked to PAX6 gene mutations and associated with complications such as glaucoma, cataracts, and corneal opacification
- The growing prevalence of genetic eye disorders, increasing awareness among ophthalmologists, and advancements in gene therapy, regenerative medicine, and corneal surface reconstruction are key drivers propelling the growth of the Aniridia Treatment market.
- North America dominated the aniridia treatment market with the largest revenue share of 38.4% in 2024, attributed to early diagnostic capabilities, advanced healthcare infrastructure, and active clinical research initiatives, particularly in the U.S. The region has seen strong uptake of investigational therapies and specialized surgical procedures for vision preservation in pediatric and adult patients
- Asia-Pacific is projected to grow at the fastest CAGR of 8.6% during the forecast period (2025–2032) due to rising patient awareness, increased ophthalmology care access, and a surge in demand for innovative therapies in countries such as Japan, China, and India
- The topical treatment segment led the aniridia treatment market with a share of 41.2% in 2024, driven by the widespread use of lubricating eye drops, anti-inflammatory agents, and medications for managing related symptoms like dry eye and glaucoma
- The minimally invasive surgery segment led the market with the largest share of 51.4% in 2024, supported by growing patient preference for procedures with less pain and quicker recovery
